Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide for Post-Operative CSF Leak Prevention
NCT04351061Phase 2Withdrawn
- Sponsor
- University of Miami
- Start
- May 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acetazolamide in cerebrospinal fluid leak, sponsored by University of Miami. Primary endpoint: Incidence of Cerebrospinal Fluid Leakage at 30 days. Planned start May 2020; status: withdrawn.
02
Drugs
acetazolamide
03
Conditions
cerebrospinal fluid leak
Beyond the preview
Go deeper on NCT04351061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04351061.